Minerva Neurosciences Completes Bridging Study

Minerva Neurosciences, Inc has concluded a bridging trial to select an improved, gastric-resistant formulation of MIN-101, the company said pre-market Thursday.

MIN-101 is a drug candidate designed to improve negative symptoms and cognitive impairment in schizophrenia.
The company says it plans to use the selected formulation in its upcoming phase 3 clinical trial, which remains on schedule for initiation in H2, as well as for the potential future submission of a new drug application.

Leave A Reply

Your email address will not be published.